Evidence map›Paper›PMID 37962669›Full record

ArticleInsights into imaging2023

Preoperative prediction of cholangiocyte phenotype hepatocellular carcinoma on contrast-enhanced MRI and the prognostic implication after hepatectomy.

Yidi Chen, Jie Chen, Chongtu Yang, Yuanan Wu, Hong Wei, Ting Duan, Zhen Zhang, Liling Long, Hanyu Jiang, Bin Song

Open access · goldAbstract read
In one paragraph

Article in Insights into imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yidi Chen *Department of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Jie Chen *Department of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Chongtu YangDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Yuanan WuBig Data Research Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Hong WeiDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Ting DuanDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Zhen ZhangDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China.
Liling LongDepartment of Radiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Hanyu JiangDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China. hanyu_jiang@foxmail.com.
Bin SongDepartment of Radiology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, 610041, Sichuan, China. songlab_radiology@163.com.ORCID http://orcid.org/0000-0002-7269-2101
Sichuan University · CNGuangxi Medical University · CNUniversity of Electronic Science and Technology of China · CN

Funding

China Post doctoral Science Foundation 2023M732435National Natural Science Foundation of China 81971571National Natural Science Foundation of China 82060310National Natural Science Foundation of China 82101997Sichuan Province Science and Technology Support Program 2021YFS0021Sichuan Province Science and Technology Support Program 2021YFS0141Sichuan Province Science and Technology Support Program 2022YFS0071
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) expressing cytokeratin (CK) 7 or CK19 has a cholangiocyte phenotype that stimulates HCC proliferation, metastasis, and sorafenib therapy resistance This study aims to noninvasively predict cholangiocyte phenotype-positive HCC and assess its prognosis after hepatectomy.

methodsBetween January 2010 and May 2022, preoperative contrast-enhanced MRI was performed on consecutive patients who underwent hepatectomy and had pathologically confirmed solitary HCC. Two abdominal radiologists separately assessed the MRI features. A predictive model for cholangiocyte phenotype HCC was created using logistic regression analysis and five-fold cross-validation. A receiver operating characteristic curve was used to calculate the model performance. Kaplan-Meier and log-rank methods were used to evaluate survival outcomes.

resultsIn total, 334 patients were included in this retrospective study. Four contrast-enhanced MRI features, including "rim arterial phase hyperenhancement" (OR = 5.9, 95% confidence interval [CI]: 2.9-12.0, 10 points), "nodule in nodule architecture" (OR = 3.5, 95% CI: 2.1-5.9, 7 points), "non-smooth tumor margin" (OR = 1.6, 95% CI: 0.8-2.9, 3 points), and "non-peripheral washout" (OR = 0.6, 95% CI: 0.3-1.0, - 3 points), were assigned to the cholangiocyte phenotype HCC prediction model. The area under the curves for the training and independent validation set were 0.76 and 0.73, respectively. Patients with model-predicted cholangiocyte phenotype HCC demonstrated lower rates of recurrence-free survival (RFS) and overall survival (OS) after hepatectomy, with an estimated median RFS and OS of 926 vs. 1565 days (p < 0.001) and 1504 vs. 2960 days (p < 0.001), respectively.

conclusionsContrast-enhanced MRI features can be used to predict cholangiocyte phenotype-positive HCC. Patients with pathologically confirmed or MRI model-predicted cholangiocyte phenotype HCC have a worse prognosis after hepatectomy. CRITICAL RELEVANCE STATEMENT: Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC and a worse prognosis following hepatectomy; these features may assist in predicting prognosis after surgery and improve personalized treatment decision-making. KEY POINTS: • Four contrast-enhanced MRI features were significantly associated with cholangiocyte phenotype HCC. • A noninvasive cholangiocyte phenotype HCC predictive model was established based on MRI features. • Patients with cholangiocyte phenotype HCC demonstrated a worse prognosis following hepatic resection.

Indexed as

Cholangiocyte phenotypeCytokeratin 19Cytokeratin 7Hepatocellular carcinomaMagnetic resonance imaging

Identifiers

PMID37962669
PMCPMC10645671
OpenAlexW4388654650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.